Aim: Tunable size ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles from 3 to 9 nm coated with polyethylene glycol phosphonate moieties have been designed for neovascularization MRI. Materials & methods: USPIO were synthesized using a nonaqueous sol-gel method. An ischemia-reperfusion rat model has been chosen for neo-angiogenesis and scanned on MRI after injection of different sized USPIO. Histological studies have been performed for USPIO localization within the tissue. Results: The magnetic properties and consequently their MRI relaxivities are drastically dependent on the crystalline core size. In vivo MRI spots were observed specifically in the ischemic area. The best MRI contrast within neovascularization is generated by 6 nm nanoparticles proving that compromise between T 2 relaxivity and physico-chemical properties is essential for the design of effective MRI contrast agent.
Among the different existing chemical composition of nanomaterials ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles are certainly the most promising material for medical applications such as cellular labeling, bio-assay, imaging, as drug carriers and for hyperthermia treatment [1, 2] . Their tunable core sizes, ranging from a few up to tens of nanometers, allow control of the magnetic properties appropriate to the intended application. For example, magnetic resonance (MR) relaxivities and in vivo biodistribution are highly dependent on USPIO sizes [3] [4] [5] . Furthermore external magnetic forces induce the movement of nanoparticles, providing various advantages in drug delivery [6] [7] [8] , cell tracking [9, 10] , cell separation [11] , transfection [12] [13] [14] , hyperthermia treatment [15, 16] and magnetic bioassays [17, 18] .
MRI using contrast agents is a very powerful technique for diagnosis in clinical medicine and biomedical research that combines high spatial resolution from MRI and functional activity from contrast agent [19] [20] [21] . Nevertheless cardiovascular disease contrast agents are not yet applicable for clinical diagnosis [22, 23] . Indeed, although USPIO are commonly considered for medical purposes, their physicochemical properties still remain insufficiently understood [24] .
Cardiovascular diseases that are initiated by tissue ischemia remain the principal cause of death in the world [25] . The recognition of microvascular dysfunction is an early and rate-determining factor in the pathological process. Ischemia injury induces neo-angiogenesis and microcirculation with an increase of vascular permeability [26] . Angiogenesis is a complex processes involving several steps, various cellular actors, several soluble angiogenic factors and different mechanical or chemical sensitive signaling pathways. All of that differ within physiological and pathological diseases. Angiogenesis imaging can therefore focus on different entities. The clinical monitoring of angiogenesis (i.e., for USPIO size control through microwave nonaqueous sol-gel method for neoangiogenesis T 2 MRI contrast agent future science group
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antiangiogenic or proangiogenic therapy) requires an imaging modality that is able to detect tissue vascularity and its changes with high sensitivity and specificity. Vascular permeability is essential for the health of normal tissues and is also an important characteristic of many disease states in which it is greatly increased [27] . MRI can define both blood volume and blood vessel permeability using dynamic enhancement of blood pool contrast agents [28] . Therefore the development of MRI contrast agent based on an increase of vascular permeability is highly interesting. USPIO with suitable particle size can passively target the tissue via the enhanced permeability and retention effect (EPR effect) [29] .
In the present study, we propose to control the USPIO size to optimize MRI T 2 relaxation times and neovascularization targeting through EPR effect. Indeed, larger hydrodynamic size nanoparticles are quickly uptaken and sequestered by the reticuloendothelial system (RES). Hence it remains a challenge to produce appropriately sized biocompatible nanoparticles (between 5 and 50 nm) with long blood circulation time both to minimize renal filtration and to limit the opsonization and RES clearance [30] [31] [32] which prevents the organs targeting [33] . Herein, we describe a facile synthesis of size tunable USPIO (3-9 nm) as MRI contrast agent, using a nonaqueous sol-gel method assisted by microwave heating. Among nonaqueous sol-gel synthesis the 'benzyl alcohol route' has been established as a very powerful technique at moderate temperature and pressure to obtain very small metal oxide nanoparticles with high crystallinity, purity and reproducibility [34] [35] [36] [37] . The microwave heating offers a substantial reduction of the reaction time (30 min) in comparison to traditional heating in an autoclave (48 h) [38] . One special advantage of the 'benzyl alcohol route' consists in the possibility of particle size control without the need of using additional surfactants or ligands. The nanoparticles are then easily surface functionalized after synthesis avoiding complex ligands exchange process. Polyethylene glycol phosphonate molecules bearing a carboxylic functionality (PO-PEG) are used as surface ligands. The phosphonate group presents high affinity for metallic surface [39] [40] [41] whereas the PEG chain improves the in vivo nanoparticles biodistribution [42, 43] . A skeletal muscle ischemia-reperfusion rat model has been chosen [44] . This model induces the formation of new vessels. One week after the surgery, the nanoparticles are injected intravenously. Neoangiogenesis and microcirculation are measured by MRI before and after USPIO injection in order to evaluate the nanoparticles as T 2 MRI contrast agent by passive targeting.
Materials & methods

USPIO synthesis Chemicals
Iron (III) acetyl acetonate (>99.9%) and Benzyl alcohol anhydrous (99.8%) were purchased from Sigma Aldrich. Phosphonate -poly(ethylene glycol) PEG -carboxylic acid MW 2500 g·mol -1 (PO-PEG) was purchased from specific polymers (ref. SP-1P-10-002). USPIO were synthesized in benzyl alcohol adapting a procedure reported previously [34] , but under microwave heating and varying the temperature to control nanoparticles sizes. Briefly, Iron (III) acetyl acetonate (0.6 mmol) was added to 5 ml of benzyl alcohol and reacted at 170, 210 or 250°C during 30 min under microwave irradiation on a Monowave 300 from Anton Paar. The resulting suspension was separated using a neodymium magnet, and the precipitate was washed with ethanol (three-times). The solid was redispersed in water at pH = 2 using an HCl solution at 10 -1 mol·l -1 (γFe 2 O 3 = 40 mg) and passivated by mixing the solution with a PO-PEG water solution (pH = 2; 400 mg). Then the excess of PO-PEG coating molecules is removed using ultrafiltration process (Amicon 30 kDa, Merck Millipore) and USPIO@PO-PEG are dispersed in water at pH 7.4 using HCl (10 -1 mol·l ) solutions.
Physico-chemical characterization
Transmission electron microscopy (TEM) images were obtained respectively using a Philips CM200 LaB 6 microscope operated at 200 kV by depositing a drop of nanoparticles suspension on carbon coated copper grids placed on a filter paper. X-ray diffraction (XRD) patterns were measured with a STOE MP diffractometer in transmission mode equipped with a molybdenum source. The fourier transform infrared (FTIR) spectra were recorded as thin films on KBr pellets on a Thermo Scientific Nicolet 380 FTIR and are reported in wavenumber of absorption (cm -1 ). The hydrodynamic size and the zeta potential of the nano complex were determined by dynamic laser light scattering on a Nano-ZS (Red Badge) ZEN 3600 device (Malvern Instruments, Malvern, UK). Quantification of coating molecules per particle was evaluated by energy-dispersive x-ray (EDX) microanalysis using a TM 3000 tabletop microscope equipped with a Swift EDX-ray 3000 microanalysis system (Oxford Instruments, UK). A vibrating sample magnetometer (Quantum Design, Versalab) was used for magnetic characterization. Vibrating sample magnetometer measures the magnetization by cycling the applied field from -30 to + 30 kOe with a step rate of 100 Oe s −1 . Measurements were performed on USPIO solutions at 1 g·l -1 at 300 K. The model of limb hind muscle ischemia-reperfusion was performed in 12 male Wistar rats. To summarize, the total blockage of perfusion of the left extensor digitorum longus (EDL) muscle was obtained after both proximal and distal tendons ligation (surgical suture 4-0, Ethicon, France). The tendon ligation was maintained under anesthesia during 1 h and then muscle was re-perfused. The right EDL muscle of the same rat was used as nonischemic control. Neo-angiogenesis was maximal (previous works of our laboratory) and evaluated after 1 week. The surgical procedure was already described elsewhere [44] and was conducted under authorization of the French Direction of the Veterinary Services (No. 2012-15/698-106).
MRI
MRI studies were acquired using a high-field (7-T) small animal MR scanner (Pharmascan, Bruker BioSpin GmbH, Rheinstetten, Germany). ) and 37°C, and thus calculate T 2 maps, a multi-slice-multi-echo sequence (TE = 11 ms; 16 echos; echo spacing = 11 ms and TR = 2500 ms) with a slice thickness of 1 mm was used to generate high-resolution coronal images (Matrix: 256 × 256, Pixel size: 0.27 × 0.13 mm).
By graphing changes in relaxation rate R 2 (R 2 = 1/ T 2 ) at different concentration, the slope represents the relaxivity r 2 .
In vivo MRI: a dedicated whole body rat coil was used for the image acquisitions. A TurboRARE-T2 (RARE method) sequence (TE = 9 ms; TR = 3,694,281 ms; NEX = 4 and RARE factor = 8) was used to generate T 2 weighted images (Matrix: 256 × 256) with a slice thickness of 1 mm at various times (t = 0; 30 min; 1 day; 1 week) after USPIO injection within physiological conditions (pH 7.4, [Na + ; Cl -] = 300 mosm·l -1 , 5% wt glucose) at a veterinary dose of 200 μmol/kg of iron.
Histological studies
Rats are sacrificed 2 weeks after imaging. EDL muscles were embedded in Tissue-Tek OCT Compound (Tissue-Tek, PA, USA), frozen in liquid nitrogen and kept at -80°C to conserve an intact morphology. For tissue analysis paraffin embedded slices where transversally thick in cross-section of 10 μm performed in the central and largest part of EDL muscle (3 mm of diameter, 10 mm 2 of surface). Then, the thick cross-sections were stained with hematoxylin/eosin for topographical examination and with Prussian Blue for iron localization. Digital-slide were acquired and analyzed with a NanoZoomer (Hammatsu, Japan).
Results
USPIO nanoparticles
USPIO are prepared by reacting a solution of iron (III) acetylacetonate in benzyl alcohol under microwave heating for 30 min at 170, 210 or 250°C and then coated with PO-PEG. Uniform USPIOs were obtained as displayed in the TEM images (Figure 1 ).
The nanoparticle size was controlled from 3 to 9 nm (Table 1 ) by varying the temperature of the synthesis from 170 to 250°C. The nanoparticle size distribution was obtained by measuring 500 particles for each sample. The standard deviation was equal to 0.2 for each sample and was deduced by simulating the diameter d distribution with a log-normal function [45] . Their crystallinity was investigated by x-ray powder diffraction (Figure 2A ).
For the three samples the patterns presented characteristic peaks for (220), (311), (400), (511), (440) and (433) The main difference consists of a few low-intensity diffractions (<5%) which are only present for the maghemite structure [35] .
When the synthesis temperature takes place at 170°C (Figure 2A , red curve) the pattern presented broad peaks which are progressively sharpening by increasing the temperature to 210°C (Figure 2A , green curve) and then 250°C (Figure 2A , blue curve). The crystallite size is determined by a Rietveld fitting of the XRD patterns (Supplementary Figure 1) . Crystallite sizes (D XRD ) increase with the temperature of synthesis and are slightly lower than D TEM for each sample (Table 1) . The crystalline structure of such USPIO is confirmed by infrared spectroscopy ( Figure 2B ) with the broad typical Fe-O (450-750 cm -1 ) vibration bands [45] from maghemite or magnetite structures.
Surface passivation & dispersion within physiological conditions
The FTIR spectrum for the free PO-PEG molecules ( Figure 2B , orange curve) is characterized by a strong vibration band due to ethylene oxide at 1100 cm -1 and the characteristic band of asymmetric phosphonate stretching [46] , ν a (PO 3 2-) at 1061 cm -1 . The PEG band dominates USPIO@PO-PEG spectrum in addition of the Fe-O vibrations bands which clearly indicates the PO-PEG coating on USPIO surface. We also notice that the characteristic band of asymmetric phosphonate stretching, ν a (PO 3 2-), is broaden and slightly blue shifted at 1042 cm -1 suggesting the PO-PEG complexation to the USPIO surface through the phosphonate group. The number of PO-PEG molecules per particle was determined by EDX analysis by measuring the ratio of iron to phosphorus signals. An average of 107, 243 and 548 PO-PEG molecules per nanoparticle were determined respectively for the nanoparticles of 3, 6 and 9 nm. These results demonstrated a linear evolution between the number of grafted PO-PEG and the surface of the nanoparticle. Thus, an average density of 2.7 ± 0.45 PO-PEG/nm 2 could be determined for each sample. This surface area is in good agreement to the results obtained previously by surface modification of oxide nanomaterials with phosphonate moieties [36, 47, 48] .
The colloidal stability of nanomaterials within physiological conditions is a key parameter for biomedical applications. The USPIO@PO-PEG formed 
highly stable dispersion over a broad range of pH (2-10) compared with the bare nanoparticles that are only stable in acidic media and agglomerates at physiological pH due to an isoelectric point around pH 6 (Supplementary Figure 2) . Within physiological conditions (pH 7.4, [Na + ; Cl -] = 300 mosm·l -1 , 5% wt glucose, T = 37°C), the as-prepared pegylated nanocrystals formed highly stable dispersion. The surface zeta potential of the three different sizes USPIO@PO-PEG are found equal to -16 ± 2 mV for the three samples ( Table 1 ). The negative charge is attributed to the terminal carboxylic function. By increasing the synthesis temperature the hydrodynamic diameters increase from 7 to 15 nm ( Figure 2C & Table 1 ). Considering a mean crystalline cores of 3, 6 and 9 nm, respectively, and a layer of PEG coating [49] , these hydrodynamic diameters suggested a very low aggregation state of the synthesized materials. Such a finding further confirms that PEG is successfully grafted onto the nanoparticle surface and USPIO stability is governed by steric repulsions independent of pH and ionic strength variations (Supplementary Figure 2) .
Magnetic behavior and MRI relaxivities
The magnetic properties of the as-synthesized USPIO are drastically modified with their particle size ( Figure 3A) . Magnetization curves indicate that 6-and 9-nm-sized nanoparticles exhibit a superparamagnetic behavior while a quasi-paramagnetic behavior is observed for 3 nm-sized nanoparticles with no saturation at 30 kOe. The value of the saturation magnetisation (M sat ) of these latter particles was estimated by plotting the magnetization M as a function of the inverse of field 1/H (Supplementary Figure 3) . The intersection of the extrapolation of the zero curve with the y-axis gives the value of M sat .
All the results are summarized in Table 1 . As the particle size increases, the magnetization at room temperature tends to increase. We especially observed a strong magnetization decrease for 3 nm USPIO. The spin canting effect, which results from structural disorder in the whole volume of the crystal structure or at the particle surface, can explain this magnetic behavior. The simplest model to characterize spin canting is the one representing a core/shell structure composed of a magnetic core and a magnetically disordered shell [45] . Considering this model, the spin canting thickness (e) [50] can be calculated from: whereby M sat is the experimental magnetization of the sample and M bulk is the theoretical saturation magnetization of bulk maghemite, taken to be 80 emu g To examine the feasibility of using the as-synthesized USPIO as T 2 MRI contrast agent, the relaxation time was measured on a 7 T MR scanner ( Figure 3B ). The r 2 relaxivities of 3, 6 and 9 nm-sized USPIOs were 8.9; 95.5 and 188.3 mM -1 ·s -1
, respectively (Table 1) . We observed that the r 2 is increasing very fast with D MAG and consequently with the particle size (D TEM ). A total of 3 nm nanoparticles presents a very low r 2 value which is due to their paramagnetic behavior whereas 9 nm USPIO exhibits high values among the best reported relaxivities compared with commercially available nanoparticulate T 2 contrast agents such as than Resovist (177 ) [51] .
In vivo MRI: ischemia hyposignals and histopathological correlations
For in vivo imaging, a skeletal muscle ischemia-reperfusion rat model has been chosen. This model induces the formation of new vessels. One week after the surgery, the nanoparticles are injected intravenously.
The nanoparticles blood circulation is estimated from the MRI variance for the left normal muscle before and after nanoparticles injection. The variance (v) is defined as:
where I 0 is MRI signal intensity before USPIO injection and I t is MRI signal intensity at the time after USPIO injection. Whatever the injected USPIO size, after injection, a negative MRI intensity is observed within the normal muscle Supplementary Figure 4 . The 3 nm USPIO presents low variance intensity due to their very low r 2 value. The most important signal decrease is obtained for 6 nm USPIO despite 9 nm USPIO exhibit the higher r 2 value. This indicates a better vascular circulation for 6 nm than 9 nm USPIO. Hence 6 nm USPIO presents the best compromise between physiological stability and MRI relaxivities. As expected 1 day after USPIO injection no more MRI contrast variance is observed due to blood circulation clearance through the RES (Supplementary Figure 5) .
Neoangiogenesis and microcirculation are measured by MRI imaging before (t = 0) and after injection (t = 30 min), the following day (t = day 1 ) and 1 week (day 8) after injection (Figure 4 ). All the images are analyzed with the same level of contrast.
Before injection, the hypersignal intensity in T 2 weighted imaging indicated the presence of an oedema around the right injured muscle as compared with left noninjured muscle (Supplementary Figure 6) . After USPIO injection we clearly observed hyposignals for 6 and 9 nm (red circle and arrow).
With pegylated 3 nm nanoparticles ( Figure 4A ), a slight negative contrast enhancement is observed at t = 30 min and 1 day after injection, indicating that the nanoparticles are circulating throughout the muscle. However, no accumulation can be observed in the ischemia area (EPR effect). These results can be explained by the low r 2 of these nanoparticles and/or their long circulation time. Concerning the 6 nm ( Figure 4B ), a large negative contrast enhancement is observed across the tissue just after injection. These results show that the nanoparticles are circulating throughout the tissue and generate a significant contrast in comparison with 3 nm nanoparticles. USPIO size control via microwave nonaqueous sol-gel method for neoangiogenesis T2 MRI contrast agent Research Article MRI 1 day after injection indicates an accumulation in the ischemic area and an elimination of nanoparticles in the rest of the tissue. Indeed, a hyposignal appears in the ischemic area while the rest of the surrounding tissue presents a similar contrast at t = 0. Finally, 8 days after the injection, a slight accumulation remains visible in the ischemic area. For 9 nm USPIO@PEG ( Figure 4C ), a slight negative contrast enhancement is observed in the whole tissue 30 min after injection, while the ischemic area presents a greater contrast with the appearance of hyposignals. These results show that the nanoparticles circulate and generate contrast in the ischemic area. The results show an accumulation in the ischemic area after 1 day injection. Indeed, a black signal appears in that area. Finally, 8 days after injection, a sharp contrast remains in the hyper-vascularized area although it is slightly weaker than the day after the injection, indicating the beginning of clearance or USPIO degradation [52] .
An analysis of tissue pathology by histological techniques (stained with hematoxylin/eosin and Blue Prussian) has been performed ( Figure 5 ).
Topographical examination was performed by hematoxylin/eosin staining ( Figure 5, left images) . The normal EDL muscle ( Figure 5A ) is characterized by the presence of cells at the periphery of myofibres in red ( Figure 5A, left, red arrow) . The ischemic injury led to muscle degeneration characterized by loss of myofibril fibers in red and apparition of fibrotic tissue in white (black arrow) with inflammatory cells infiltration (purple round cells; red arrow). The presence of USPIO is evidenced by Blue Prussian staining (right images) and is only present within the injury muscle whatever the USPIO size (Supplementary Figure 7) . USPIO (brown; blue arrow) are spread into the tissue around micro vessels (green arrow).
Discussion
The goal of this study was to improve the contrast MRI and early detection of neoangiogenesis and microcirculation by passive targeting (EPR effect) through the development of iron oxide nanoparticles of different sizes. The model used is the ischemia/reperfusion of the lower limb in the rat.
USPIO Magnetic behavior toward MRI signal optimization
Magnetic (D MAG ) and Xray (D XRD ) sizes are in good agreement for each nanoparticle sizes and are slightly lower that TEM sizes (D TEM ). This confirms a core/ shell structure composed of a magnetic core and a magnetically disordered shell. When the spin canted layer is assumed as 0.7 nm, 85% of spins in 3nm-sized USPIO are canted, whereas only 55 and 40% of spins are respectively canted in 6-and 9-nm-sized nanoparticles. The dramatically decreased magnetization and r 2 of 3 nm USPIO can be explained by the significant increase of the disordered shell over the ordered magnetic core. By increasing the particle size, the percentage of ordered spins increased and consequently the magnetization and relaxivities increase to reach r 2 high values as those of commercial formulations (r 2 = 160-177 mM -1 ·s -1
) [51] . From a strictly physical point of view the 9-nm-sized USPIO appears as the ideal T 2 MRI contrast agent candidate.
USPIO size effects and ischemia targeting through EPR effect
In vivo MRI results indicate that the 6 nm nanoparticles are excellent contrast agents (Figure 4) . Indeed the visible accumulation (MRI black signals) in the ischemic area is demonstrating a passive accumulation of nanoparticles in the tissues. MRI studies show that the 3 nm-sized nanoparticles cannot be used as T 2 contrast agents due to their very low r 2 relaxivity despite their accumulation within the ischemic injury. In contrast, 6-and 9-nm-sized nanoparticles generate an interesting contrast for T 2 weight imaging within in vitro as well as in vivo studies. Their accumulation in the ischemic area highlights their potential use as a passive targeting agent. Rapidly (t = 30 min) after the injection of 6 nm USPIO MRI highlights a very strong uniform contrast within the EDL muscle ( Figure 4B ) demonstrating their widespread circulation. It is also noted that nanoparticles of 6 nm generate a greater contrast on ischemia lesion than the nanoparticles of 9 nm, although the relaxivity is less important. This phenomenon can be explained by their enhanced in vivo circulation and retention by EPR effect. Indeed high stealth of the assynthesized nanoparticles can be attributed to a high density of PEG moieties at the nanoparticle surface (2.7 ± 0.45 PO-PEG/nm 2 ), therefore limiting the interaction with proteins present in biological media and so decreasing the opsonization. This phenomenon leads to a low elimination of the nanoparticles by the RES.
The ischemia MRI is confirmed by the histopathological correlations ( Figure 5 ). USPIO are spread into the whole tissue around microvessels but only for the ischemic injured muscle and not for the control one. Histopathological studies confirm the USPIO targeting to microvascularization by EPR effect through their extravasation into the injured tissue contrarily to normal muscle without endothelial barrier disruption.
Conclusion & future perspective
Herein, we describe a facile synthesis of size tunable USPIO from 3 to 9 nm as MRI contrast agent, using a nonaqueous sol-gel method assisted by microwave heating. The magnetic properties and consequently their MRI relaxivities are drastically dependent on the crystalline core size. About 3 nm-sized USPIO has dramatically low T 2 relaxivity whereas 9 nm-sized exhibits high r 2 close to 200 mM -1 ·s -1
. The nanoparticles are functionalized with a high density of phosphonatepegylated moieties inducing a very good stability in biological media. These results have allowed considering in vivo experiments. The in vivo experiments showed that the nanoparticles circulated throughout the vascularization of the rat and, for the 6-and 9-nmsized nanoparticles, black MRI spots were observed in the ischemic area. Although 6 nm nanoparticles had a lower relaxivity than the 9 nm ones, the contrast generated by these nanoparticles in neovascularization is more important due to their better ischemia targeting than nanoparticles of 9 nm. The histological study confirms the USPIO accumulation within the ischemic area and demonstrates higher iron accumulation for 6 than 9 nm nanoparticles. These results obtained 1 week after injection demonstrate the USPIO passive targeting through EPR effect. Hence we demonstrated that fine tuning and control of chemical-physical properties of nanomaterials design is a key point for the stability and therefore the biodistribution of such nanomaterials. The controlled nanoparticles size and the PEG passivation reduce the RES clearance, enhance their blood circulation time and permit ischemia targeting through EPR effect. The results presented here address a major issue: the difficulty to increase peripheral blood circulation with the limitation of clearance by liver and spleen. This proof-of-concept study will be completed by a pharmacokinetic investigation for quantitatively confirming the highest accumulation
Executive summary Background
• MRI using contrast agents is a very powerful technique for diagnosis that combines high spatial resolution from MRI and functional activity from contrast agent.
• Nevertheless sensitivity and selectivity improvement of MRI contrast agents are still necessary for clinical diagnosis.
• With this aim we described a facile synthesis of size tunable ultrasmall superparamagnetic iron oxide (USPIO) for MRI contrast agent optimization.
Results
• USPIO nanoparticles covered with PEG moieties were successfully synthesized with various sizes from 3 to 9 nm.
• Their magnetic properties and consequently their MRI relaxivities are drastically dependent on the crystalline core size.
• In vivo MRI and histological study evidences the USPIO targeting to neovascularization through enhanced permeability and retention effect.
Discussion
• The ratio between the disordered shell and the ordered magnetic core explained the large dependence of MRI contrast with the USPIO size leading to high T2 MRI contrast agent for 9-nm-sized USPIO.
• About 6-nm-sized USPIO can detect ischemia in rat model with high sensitivity and might be an efficient molecular imaging agent for MRI.
• Although 6-nm-sized USPIO had a lower MRI relaxivity than the 9 nm ones, the in vivo contrast generated by these nanoparticles in neovascularization is more important due to their better ischemia passive targeting.
• Hence we demonstrated that fine tuning and control of chemical-physical properties of nanomaterials design is a key point for the stability and therefore the biodistribution of such nanomaterials.
of 6 nm USPIO in the neo-angiogenic vessels. In addition, conjugating this system with targeting molecules such as peptides or antibodies will represent an opportunity for functional diagnostic imaging.
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